Using Available Evidence and Guidelines for Managing an Evolving AML Treatment Paradigm

ClinicalXchange Oncology podcasts

Presenter:

Gail J. Roboz MD
Professor of Medicine
Director, Clinical and Translational Leukemia Program
Weill Medical College of Cornell University
New York-Presbyterian Hospital
New York, New York, United States

This brief program will begin with a review of NCCN Guidelines® Recommendations for the treatment of AML in individuals 60 years of age or older. Next, the results of the BRIGHT AML 1003 trial comparing glasdegib + LDAC to LDAC alone, the VIALE-A trial comparing venetoclax + azacitidine vs azacitidine alone, and a comparison of CPX-351 vs standard of care cytarabine + daunorubicin (7 + 3 regimen) for induction and consolidation, will be reviewed. The faculty will discuss FLT3 and IDH inhibitor approvals for AML, IDK differentiation syndrome, and measuring MRD in AML. Finally, results of a trial examining oral azacitidine and a meta-analysis of 5 trials examining gemtuzumab ozogamicin will be reviewed.https://www.clinical-care.org/resource-center-details/using-available-evidence-and-guidelines-for-managing-an-evolving-aml-treatment-paradigm

Follow along with the slideset located here:
https://bit.ly/3lJNHYC